ATE435911T1 - Antisens-oligonukleotide die fähig sind die herstellung von kapillarröhrchen zu hemmen - Google Patents

Antisens-oligonukleotide die fähig sind die herstellung von kapillarröhrchen zu hemmen

Info

Publication number
ATE435911T1
ATE435911T1 AT02751246T AT02751246T ATE435911T1 AT E435911 T1 ATE435911 T1 AT E435911T1 AT 02751246 T AT02751246 T AT 02751246T AT 02751246 T AT02751246 T AT 02751246T AT E435911 T1 ATE435911 T1 AT E435911T1
Authority
AT
Austria
Prior art keywords
animals
microm
day
nucleic acid
antisense
Prior art date
Application number
AT02751246T
Other languages
German (de)
English (en)
Inventor
Salman Al-Mahmood
Original Assignee
Gene Signal Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Signal Int Sa filed Critical Gene Signal Int Sa
Application granted granted Critical
Publication of ATE435911T1 publication Critical patent/ATE435911T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT02751246T 2001-06-14 2002-06-14 Antisens-oligonukleotide die fähig sind die herstellung von kapillarröhrchen zu hemmen ATE435911T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107805A FR2826010B1 (fr) 2001-06-14 2001-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales
PCT/FR2002/002067 WO2002103014A2 (fr) 2001-06-14 2002-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires

Publications (1)

Publication Number Publication Date
ATE435911T1 true ATE435911T1 (de) 2009-07-15

Family

ID=8864317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751246T ATE435911T1 (de) 2001-06-14 2002-06-14 Antisens-oligonukleotide die fähig sind die herstellung von kapillarröhrchen zu hemmen

Country Status (13)

Country Link
US (3) US7417033B2 (enExample)
EP (2) EP1409672B1 (enExample)
JP (1) JP4153421B2 (enExample)
AT (1) ATE435911T1 (enExample)
AU (1) AU2002345669B9 (enExample)
CA (1) CA2451874C (enExample)
CY (1) CY1109464T1 (enExample)
DE (1) DE60232883D1 (enExample)
DK (1) DK1409672T3 (enExample)
ES (1) ES2331835T3 (enExample)
FR (1) FR2826010B1 (enExample)
PT (1) PT1409672E (enExample)
WO (1) WO2002103014A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031277A2 (en) * 2005-09-14 2007-03-22 Medizinische Universität Wien Means and methods for diagnosing endometriosis
US8032556B1 (en) * 2008-03-07 2011-10-04 Symantec Corporation Systems and methods for user profile data delivery
US8470997B2 (en) 2009-02-05 2013-06-25 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US8580947B2 (en) 2009-02-05 2013-11-12 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US20120041047A1 (en) * 2010-08-10 2012-02-16 Gene Signal International Sa Injectable Pharmaceutical Composition for Preventing, Stabilizing and/or Inhibiting Pathological Neovascularization-Related Conditions
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
EP2540828A1 (en) 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
WO2013001080A1 (en) 2011-06-30 2013-01-03 Gene Signal International Sa Composition comprising inhibitors of irs-1 and of vegf
US9359604B2 (en) 2012-07-03 2016-06-07 Gene Signal International Sa Inhibitor of IRS-1 for treating skin disorders
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572508A4 (en) * 1991-01-18 1995-03-29 Joslin Diabetes Center Inc NUCLEIC ACID ENCODING THE INSULIN RECEPTOR SUBSTRATE-1 (IRS-1), IRS-1 PROTEIN, DISEASES AND THERAPY ASSOCIATED WITH IRS-1 METABOLISM.
FR2733913B1 (fr) * 1995-05-09 1997-08-01 Sanofi Sa Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant
US6498139B1 (en) * 1997-09-29 2002-12-24 Daiichi Pharmaceutical Co., Ltd. Remedies for diseases caused by insulin resistance
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
EP1186667B1 (en) * 1999-05-18 2007-07-18 Dnavec Research Inc. Envelope gene-deficient virus vector of paramyxoviridae

Also Published As

Publication number Publication date
CA2451874A1 (fr) 2002-12-27
DK1409672T3 (da) 2009-11-09
CY1109464T1 (el) 2014-08-13
WO2002103014A2 (fr) 2002-12-27
US7417033B2 (en) 2008-08-26
JP2004538272A (ja) 2004-12-24
WO2002103014A3 (fr) 2004-02-26
US20040162257A1 (en) 2004-08-19
US20080293658A1 (en) 2008-11-27
DE60232883D1 (de) 2009-08-20
AU2002345669B9 (en) 2006-06-29
EP1409672B1 (fr) 2009-07-08
EP1409672A2 (fr) 2004-04-21
ES2331835T3 (es) 2010-01-18
EP2166095A3 (fr) 2012-01-04
FR2826010A1 (fr) 2002-12-20
US20090082292A1 (en) 2009-03-26
JP4153421B2 (ja) 2008-09-24
CA2451874C (fr) 2013-07-30
PT1409672E (pt) 2009-11-04
US8828959B2 (en) 2014-09-09
EP2166095A2 (fr) 2010-03-24
US7855184B2 (en) 2010-12-21
FR2826010B1 (fr) 2005-02-25
AU2002345669B2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
CY1109464T1 (el) Αντισυνθετικα ολιγονουκλεοτιδια ικανα να αναστειλουν την δημιουργια τριχοειδων σωληνων
George et al. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats
Ashcroft et al. The effects of ageing on cutaneous wound healing in mammals
EP1352061B9 (de) Verfahren zur hemmung der expression eine zielgens
Calza et al. Neural stem cells and cholinergic neurons: regulation by immunolesion and treatment with mitogens, retinoic acid, and nerve growth factor
Yun et al. STAT3 activation in microglia exacerbates hippocampal neuronal apoptosis in diabetic brains
Panzer et al. The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis
DE50214266D1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
ES2061416T3 (es) Ribozimas modificadas.
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERINEXPRESSION
DE69005352D1 (de) Antikörper enthaltende Verabreichungssysteme für biologische verhaltensändernde Stoffe.
CA2229171A1 (en) Method of modulating gene expression with reduced immunostimulatory response
Ricardo et al. Angiotensinogen and AT1 antisense inhibition of osteopontin translation in rat proximal tubular cells
Lee et al. Estrogen-mediated protection against HIV Tat protein-induced inflammatory pathways in human vascular endothelial cells
EP1549767A4 (en) MODULATION OF EXPRESSION OF FORKHEAD BOX O1A
ATE475716T1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
Bothwell Neurotrophin function in skin
ES2188581T3 (es) Modulacion por oligonucleotidos de la adherencia celular.
EP1556486B1 (de) Wirksame und stabile dna-enzyme
KR930702995A (ko) 세포증식 매트릭스 및 그 용도
Sahlberg et al. Tenascin‐C in developing mouse teeth: expression of splice variants and stimulation by TGFβ and FGF
Kinbara et al. Transforming growth factor‐β isoforms differently stimulate proα2 (I) collagen gene expression during wound healing process in transgenic mice
BE1002375A3 (fr) Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie.
Söderström et al. In vitro toxicity of methyl mercury: effects on nerve growth factor (NGF)-responsive neurons and on NGF synthesis in fibroblasts

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1409672

Country of ref document: EP